Value of Health
We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions to. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong.
This is the impetus behind MassBio's Value of Health series, a major, new initiative to explore the future of the biotech industry through the prism of drug pricing. Guided by experts, we will produce a series of three whitepapers and related events in 2019 that together seek to answer the question: is the current biotech pricing model sustainable, and if not, what needs to change?
Don't miss your opportunity to be a part of this conversation. Download our first whitepaper today to learn about the changing access & reimbursement landscape early to mid-stage biopharma companies are in, and what actions they should take to ensure patient access.
Part I: Defining Value
This whitepaper explores the value equation from the perspectives of the various healthcare stakeholders, drawing from insights from a MassBio advisory group. Its goal is to educate biopharma companies, especially those in early and mid-stages, about the current and expected environment they’re operating in, and considerations these companies must make to ensure patient access when their drug comes to market. It is our belief that the sooner companies start thinking about value and how they will demonstrate it, the fewer hurdles to patient access will exist. Learn more.
Part II: Public Payers in the U.S. & Abroad
Part II of the series will look at current environment with Medicare and Medicaid in the U.S., proposed changes that could impact access and reimbursement, and how something like Medicare for All would impact the biopharma industry. It’ll also consider international models of assessing value and determining access, including those key markets where the government is the sole payer. Learn more.
Part III: Potential Disruptors' Impact on the System
The healthcare system is evolving as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing, patient access, and the ability to track and analyze data? How will the joint healthcare venture between Amazon, J.P. Morgan and Berkshire Hathaway (Haven) change how employers offer healthcare? What new players are disrupting the value equation? We'll attempt to answer those questions and more. Learn more.